Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically

被引:21
作者
Mohamood, Abdiaziz S.
Guler, Mehmet L.
Xiao, Zuoxiang
Zheng, Dongfeng
Hess, Allan
Wang, Yi
Yagita, Hideo
Schneck, Jonathan P.
Hamad, Abdel Rahim A.
机构
[1] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
[3] Alexion Pharmaceut Inc, Cheshire, CT USA
[4] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan
关键词
D O I
10.2353/ajpath.2007.070148
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Spontaneous mutation of Fas (lpr) or FasL (gld) completely protects nonobese diabetic mice from autoimmune diabetes but also causes massive double-negative T-cell lymphoproliferation. in this study, we used bone marrow chimeras and adoptive transfer analysis to investigate further the role of FasL in the pathogenesis of autoimmune diabetes and to determine whether gld-induced tolerance and double-negative T-cell lymphoproliferation can be uncoupled from each other. We show that FasL expressed on hematopoietic and nonhematopoietic compartments plays nonredundant roles in the pathogenesis of autoimmune diabetes. Mutation of FasL in either compartment interferes with the autoimmune process and prevents onset of diabetes, but FasL expressed in the hematopoietic compartment is the dominant regulator of T-cell homeostasis. Furthermore, pathogenesis of diabetes is dependent on normal FasL expression in both compartments, whereas only minimal FasL function is required to maintain T-cell homeostasis. Consequently, partial disruption of FasL protects from autoimmune diabetes without causing T-cell lymphoproliferation. This is demonstrated genetically in nonobese diabetic-gld/+ mice and pharmacologically by using FasL-neutralizing antibody. These results have important implications for understanding the role of the Fas pathway in pathogenesis of autoimmune diseases and for designing novel FasL-modulating therapies.
引用
收藏
页码:97 / 106
页数:10
相关论文
共 42 条
[1]  
ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147
[2]   Mechanisms of β cell death in diabetes:: A minor role for CD95 [J].
Allison, J ;
Strasser, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (23) :13818-13822
[3]   The NOD mouse: A model of immune dysregulation [J].
Anderson, MS ;
Bluestone, JA .
ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :447-485
[4]   Effective destruction of Fas-deficient insulin-producing β cells in type 1 diabetes [J].
Apostolou, I ;
Hao, ZY ;
Rajewsky, K ;
von Boehmer, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (07) :1103-1106
[5]  
Ashany D, 1999, J IMMUNOL, V163, P5303
[6]   CELL-AUTONOMOUS FAS (CD95) FAS-LIGAND INTERACTION MEDIATES ACTIVATION-INDUCED APOPTOSIS IN T-CELL HYBRIDOMAS [J].
BRUNNER, T ;
MOGIL, RJ ;
LAFACE, D ;
YOO, NJ ;
MAHBOUBI, A ;
ECHEVERRI, F ;
MARTIN, SJ ;
FORCE, WR ;
LYNCH, DH ;
WARE, CF ;
GREEN, DR .
NATURE, 1995, 373 (6513) :441-444
[7]   The role of Fas in autoimmune diabetes [J].
Chervonsky, AV ;
Wang, Y ;
Wong, FS ;
Visintin, I ;
Flavell, RA ;
Janeway, CA ;
Matis, LA .
CELL, 1997, 89 (01) :17-24
[8]   LPR AND GLD - SINGLE GENE MODELS OF SYSTEMIC AUTOIMMUNITY AND LYMPHOPROLIFERATIVE DISEASE [J].
COHEN, PL ;
EISENBERG, RA .
ANNUAL REVIEW OF IMMUNOLOGY, 1991, 9 :243-269
[9]   Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells [J].
Desbarats, J ;
Duke, RC ;
Newell, MK .
NATURE MEDICINE, 1998, 4 (12) :1377-1382
[10]   AUTOCRINE T-CELL SUICIDE MEDIATED BY APO-1/(FAS/CD95) [J].
DHEIN, J ;
WALCZAK, H ;
BAUMLER, C ;
DEBATIN, KM ;
KRAMMER, PH .
NATURE, 1995, 373 (6513) :438-441